# Shanghai Zhongshan Hospital: Phase 2 study in Advanced Biliary Tract Cancer (39 participants)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Sponsor type | Academic and hospital |
| Study | Safety and Efficacy of Gemcitabine, Toripalimab and Dose- Modified Lenvatinib in Elderly Patients With Advanced Biliary Tract Cancer Intolerant to Conventional Chemotherapy |
| NCT ID | NCT07897565 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | Advanced Biliary Tract Cancer |
| Intervention types | drug |
| Target enrollment | 39 |
| Posted | 2026-10-27 |
| Planned start | 2026-10-12 |
| Event | Newly registered study |
| Event date | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07897565). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.